SARS-CoV-2/COVID-19 Prevalence Study
SARS-CoV-2 Prevalence Study
1 other identifier
observational
26,741
2 countries
15
Brief Summary
The COVID-19 Prevention Network (CoVPN) is doing a study to estimate the number of people who have or have had the SARS-CoV-2 virus in different communities in the United States. This study is being done to help determine the best places to perform future research studies that will test new drugs for treatment or prevention of COVID-19.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2021
Shorter than P25 for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 19, 2020
CompletedFirst Posted
Study publicly available on registry
December 8, 2020
CompletedStudy Start
First participant enrolled
February 4, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 12, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 12, 2021
CompletedOctober 4, 2021
September 1, 2021
6 months
November 19, 2020
September 29, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
To estimate the prevalence of SARS-CoV-2 IgG seropositivity among individuals in communities surrounding selected NIAID clinical research sites
Baseline
Secondary Outcomes (7)
To estimate prevalence of SARS-CoV-2 infection based on results of SARS-CoV-2 RNA testing
Baseline
To estimate prevalence of SARS-CoV-2 infection by presence versus absence of symptoms consistent with COVID-19
Baseline
To estimate seroprevalence of SARS-CoV-2
Baseline
To assess association between demographic, clinical and social factors with SARS-CoV-2 infection and seroprevalence, with particular interest in racial and ethnic health disparities.
Baseline
To estimate potential size of populations for referral to COVID-19 prevention and treatment studies
Baseline
- +2 more secondary outcomes
Study Arms (3)
Senior Living Facilities
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
Outpatient Healthcare Facilities
Adults attending outpatient healthcare in neighborhoods of selected research sites
General Communities
Adults and children (\>2 months of age) in neighborhoods of selected research sites
Eligibility Criteria
Adults residing in nursing homes or attending outpatient healthcare facilities in neighborhoods of selected research sites. Adults and children (\>2 month of age) in neighborhoods of selected research sites.
You may qualify if:
- Adults residing in senior living facilities or attending outpatient healthcare facilities:
- At least 18 years of age
- Willing and able to provide informed consent or consent has been provided by legal representative (for those with mental incapacity in senior living facilities)
- Recruited from a selected facility
- Adults and children from select neighborhoods of research site communities:
- Adults and children \> 2 months of age
- For individuals \< 18 years old, a guardian must be present (in person or by phone for those 15 - 17 years old)
- Willing and able to provide consent (or assent for individuals 7-17 years old, parent/guardian will provide consent for all minors)
- Recruited from a selected venue
You may not qualify if:
- Previous enrollment in this study, either from the same or another CRS community.
- Any condition that, in the opinion of the study staff, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (15)
Children's Hospital Colorado CRS
Aurora, Colorado, 80045, United States
U of Miami, IDRU at Jackson Memorial Hospital CRS
Miami, Florida, 33136, United States
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308, United States
UIC Project Wish CRS
Chicago, Illinois, 60612, United States
New Orleans Adolescent Trials Unit CRS
New Orleans, Louisiana, 70118, United States
John's Hopkins CRS
Baltimore, Maryland, 21218, United States
New Jersey Medical School CRS
Newark, New Jersey, 07103, United States
Harlem Prevention
New York, New York, 10027, United States
Physicians & Surgeons CRS
New York, New York, 10032, United States
Bronx Prevention Center
New York, New York, 10451, United States
Cincinnati CRS
Cincinnati, Ohio, 45229, United States
Penn Prevention CRS
Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, 15260, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
St. Louis University VTEU-CAIMED-PHSU
Ponce, Puerto Rico
Related Links
Biospecimen
Blood collection, nasal mid-turbinate swab, and saliva
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jessica Justman, MD
Departments of Epidemiology and Medicine, Columbia University
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 19, 2020
First Posted
December 8, 2020
Study Start
February 4, 2021
Primary Completion
August 12, 2021
Study Completion
August 12, 2021
Last Updated
October 4, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share